{
    "clinical_study": {
        "@rank": "148142", 
        "arm_group": [
            {
                "arm_group_label": "PCP with true CMV co-infection"
            }, 
            {
                "arm_group_label": "PCP with innocent bystander CMV"
            }, 
            {
                "arm_group_label": "PCP without any evidence of CMV"
            }
        ], 
        "brief_summary": {
            "textblock": "PCP (Pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in\n      immunocompromised patients including HIV-infected patients, transplant recipients, and\n      immunosuppressant users. About one third of non-HIV patients with PCP have the evidence of\n      co-infection with CMV. In this difficult clinical situation, physicians have difficulty to\n      decide on whether anti-CMV treament will help patients with any evidence of CMV\n      co-infection. However, there is no objective test to differentiate true co-infection of CMV\n      from innocent bystander of CMV in those with PCP. The investigators thus evaluate the\n      usefulness of CMV-specific ELISPOT assay in patients with PCP to differentiate true\n      co-infection of CMV from inocent bystander of CMV. This findings may guide physicians to\n      decide anti-CMV treatment in patients with PCP and CMV co-infection."
        }, 
        "brief_title": "Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-HIV Patients With Pneumocystis Jiroveci Pneumonia", 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PCP (Pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in\n      immunocompromised patients including HIV-infected patients, transplant recipients, and\n      immunosuppressant users. About one third of non-HIV patients with PCP have the evidence of\n      co-infection with CMV. In this difficult clinical situation, physicians have difficulty to\n      decide on whether anti-CMV treament will help patients with any evidence of CMV\n      co-infection. However, there is no objective test to differentiate true co-infection of CMV\n      from innocent bystander of CMV in those with PCP. The investigators thus evaluate the\n      usefulness of CMV-specific ELISPOT assay in patients with PCP to differentiate true\n      co-infection of CMV from inocent bystander of CMV. This findings may guide physicians to\n      decide anti-CMV treatment in patients with PCP and CMV co-infection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis of PCP based on PCP immunohistochemistry or PCP PCR\n\n          -  age 16 or more\n\n          -  agree with written informed consent\n\n          -  WBC count 2000/uL or more\n\n        Exclusion Criteria:\n\n          -  HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Non-HIV patients with PCP"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109887", 
            "org_study_id": "S2013-1999-0005", 
            "secondary_id": "2014-0198"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pneumocystis jiroveci, cytomegalovirus, co-infection", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "kimsunghanmd@hotmail.com", 
                "last_name": "Sung-Han Kim, MD", 
                "phone": "82-2-3010-3305"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Sung-Han Kim, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "3", 
        "official_title": "Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)", 
        "overall_contact": {
            "email": "kimsunghanmd@hotmail.com", 
            "last_name": "Sung-Han Kim, MD", 
            "phone": "82-2-3010-3305"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CMV co-infection is defined as (1) positive BAL (bronchoalveolar lavage fluid) CMV culture and (2) ganciclovir therapy for at least 1 week.", 
            "measure": "CMV co-infection", 
            "safety_issue": "No", 
            "time_frame": "1 month after the diagnosis of PCP"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109887"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Sung-Han Kim", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall mortality", 
                "safety_issue": "No", 
                "time_frame": "1 month after the diagnosis of PCP"
            }, 
            {
                "description": "innocent bystander CMV infection\npositive blood CMV antigenemia and/or positive blood or BAL CMV qPCR without positive BAL CMV culture\nclinical improvement without ganciclovir therapy for at least 1 week", 
                "measure": "innocent bystander CMV infection", 
                "safety_issue": "No", 
                "time_frame": "1 month after the diagnosis of PCP"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}